lobradimil
Term · Oncology and biomedicine · MLC-T-ONC-004898
A substance that is being studied for its ability to help other drugs reach the brain. It belongs to the family of drugs called bradykinin agonists. Also called RMP-7.
A synthetic analog of bradykinin. Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates B-2 receptors expressed on the surface of brain capillary endothelial cells, thereby reversibly increasing the permeability of the blood-brain barrier (BBB). Compared to bradykinin, this agent possesses enhanced receptor selectivity, greater plasma stability, and a longer half-life.
| Identifier | MLC-T-ONC-004898 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | RMP-7 |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-004898",
"term": "lobradimil",
"field": "Oncology and biomedicine",
"definitions": [
"A substance that is being studied for its ability to help other drugs reach the brain. It belongs to the family of drugs called bradykinin agonists. Also called RMP-7.",
"A synthetic analog of bradykinin. Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates B-2 receptors expressed on the surface of brain capillary endothelial cells, thereby reversibly increasing the permeability of the blood-brain barrier (BBB). Compared to bradykinin, this agent possesses enhanced receptor selectivity, greater plasma stability, and a longer half-life."
],
"synonyms": [
"RMP-7"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/lobradimil/"
}
Record 10,262 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.